We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PHC Plant Health Care Plc

0.00 (0.00%)
Last Updated: 08:00:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Plant Health Care Plc LSE:PHC London Ordinary Share GB00B01JC540 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.73 3.64 3.98 - 101,405 08:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pesticides, Agric Chems, Nec 11.77M -9.48M -0.0278 -1.34 12.74M
Plant Health Care Plc is listed in the Pesticides, Agric Chems sector of the London Stock Exchange with ticker PHC. The last closing price for Plant Health Care was 3.73p. Over the last year, Plant Health Care shares have traded in a share price range of 3.20p to 12.00p.

Plant Health Care currently has 341,532,952 shares in issue. The market capitalisation of Plant Health Care is £12.74 million. Plant Health Care has a price to earnings ratio (PE ratio) of -1.34.

Plant Health Care Share Discussion Threads

Showing 726 to 748 of 1350 messages
Chat Pages: Latest  30  29  28  27  26  25  24  23  22  21  20  19  Older
At first glance all good with increase in sales and gross margin compared to H1 19 and reduction in expenses and cash used in operations. However note that Cash used in operations at us2.1m in H1 20 was higher than the 1.5m in H2 19.
I see that it was a half of two quarters although the difficulties in Q2 were well highlighted in the Outlook section of the 2019 results statement..
Will be interesting to know how the Labour situation in the US fruit business was resolved.

Decent update.
Anyone understand what ius the position ref UK authorization given the tests going on in the UK as per May 27 RNS.
I appreciate UK small market compared to US/Brazil but begs the question on EU approvals.

Great news 14p here we come and once approval is obtained for Brazil whey hey
(PPS) another great recovery play too
ny boy

US Corn

- PHC 279 increased corn yields by 9-15% when applied as a foliar spray, creating potential grower value of $54 - $82 per acre at current average prices.

- PHC279 significantly improved the control of two key corn diseases by as much as 50%, even under heavy disease pressure.

Spring wheat

- PHC279 increased yield by as much as 17% when added to the standard disease control program, which is worth $86 per acre at current prices.


- PHC279 increased yield by as much as 22% compared to fungicides alone.

- PHC279 also improved disease control as much as 31% following foliar application.

In the US, 91m acres of corn were planted in 2019. Severe southern rust disease can routinely reduce corn yields as much as 25 bushels per acre. At current prices, this would equate to lost revenue for the farmer of $79 per acre. In historical epidemics of southern corn leaf blight, yields were reduced by 20 to 25 percent nationwide, resulting in an estimated $1 billion loss in harvest. In the Company's trials, when PHC279 was applied together with a leading chemical fungicide, it significantly improved control of both diseases compared to the fungicide treatment alone, and yields were increased by as much as 26 bushels per acre depending on application timing. Even a more modest benefit of 5-10 bushels per acre is likely to provide an attractive return on investment in the potential range of 5:1 to 8:1 for farmers who apply PHC279 to their fields.

In the UK, when PHC279 was applied to spring wheat seeds prior to planting, followed by adding it to the standard spray fungicide program, yield was increased by as much as 17% in fields with Septoria tritici blotch, the major disease of wheat in the UK. At current prices, this yield benefit would be worth $86 per acre to the farmer.

Lettuce drop disease is a major pathogen affecting US lettuce cultivation. In a series of US field trials inoculated with Sclerotinia, the causative agent of lettuce drop disease, PHC279 treated plants yielded as much as 22% more than plants treated only with the standard chemical fungicide program. With an acre of lettuce worth more than $10,000 in the US in 2018, even a modest increase in lettuce yield will likely justify the cost of applying PHC279.

Plant Health Care's PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, this is a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice. PHC279 may allow farmers to reduce applications of toxic fungicides or to achieve better control of disease.

Gary L. Cloud, Ph.D., a research agronomist and owner of GLC Consulting, Inc. participated in the testing of PHC279 in corn this season, and offered the following, "There was heavy disease pressure and PHC279 provided visible improvement in disease control and higher yield compared to the standard fungicide when applied early in the growing season. That is somewhat amazing due to the time that elapsed between application and harvest. I believe PHC279 will be a valuable tool for corn growers struggling to control disease in their fields."

Chris Richards, CEO of Plant Health Care, said "We are extremely encouraged with the performance of PHC279 in multiple key crops. Building on our recent success with PHC279 for the control of Asian soybean rust in Brazil, it is clear PHC279 will have important benefits for farmers in many crops. The registration of our first PREtec peptide is progressing in the US and Brazil and the scale-up of manufacturing has started. We are excited about the potential for products based on our PREtec peptides, which are targeting markets with an initial opportunity of $5 billion. We aim to launch the first peptides as soon as regulatory permits have been obtained, to offer these valuable new tools to growers in the US and other countries."

Impressive to say the least, still a long term hold here for me 100p +
ny boy
mm upped bid by 42%

Pretty good trial results today.

Happy to wait for the eventual rerate.

I listened to the Edison TV interview with Dr Richards and went through the prelins in a bit more depth.
He reiterated what they said in the prelims ie that even in the worst case scenario they had cash till early 2022.
Note the March 21 RNS referred to approvals for PHC 279 but I could see no reference to that in the prelims.
I need to say that on further reflection I have got confused about how strong sales will be in 2020 given Brazil ethanol and also US fruit industry with both labour issues and disappearance of restaurant trade,
A slow burn but at least they have plenty of cash.

I see that the shares have been marked down a fraction this morning and that seems a logical reading of the results.
Good that Q1 revenues were up 10pc on last year and especially good that they got the new financing but the Brazil ethanol market shows how easily they can get tripped up.
On the basis of a quick read I do not see myself buying more or selling given all the uncertainties they spell out with Covid.

It went mainly to II but under 3% holding. I took a load but got scaled back 30%. I think this company will do very well over the next two seasons. I like their partner in Brazil re. sugarcane, I like the incredible yield improvements across the board for its products. Way better than Plant Impact ..back in the day!
here and there
I assume Ospraie will go to 29.9% and then...
I see that of the 44.6m shares just raised that important shareholders Griffiths and L Odier did not participate and that Ospraie took about 19.7m of the new shares.I assume that none of the other 25m odd shares went to people with sizeable holdings otherwise we would have had a RNS,
Interesting that they limited the share raising to an amount which even before expenses was less than 2019 cash burn. Suggests that they have a good deal of confidence, which is manifest in the directors'participation.
I can understand why you say what you said. However I am sure that you have also seen many occasions when AIM companies have done an Equity raise which has excluded private shareholders and the price has subsequently fallen below the share offer price.

The placing was heavily over subscribed. I took part. Got scaled back to 60 % of my order. Think they are going to have a good year
here and there
It's a discraceful way to treat PIs IMO. TXP were similar last week.
Well done Cerrito,look back through the other thread if you want a clearer picture.As I have said before there is value in the IP and at some point it may be realized but for private investors its a rinse repeat story
Have been looking at putting my toe in this water and just as well for me that I dithered.
Spooky that they raised US3m pre expenses in November and had just US2.4 in cash/equivalents at year end,

What a disgrace,massive discounted placing again from the management that keep insisting that they are funded until cash flow positive.
"The Issue Price represents a discount of approximately 43.9 per cent. to the closing mid-market price on 21 February 2020, being the latest practicable date before this Announcement."

Playing out nicely

PPS too

It’s a good!

ny boy
Nice bowl forming in the chart.
Great News and Chris Richards is a top guy with skin in the game
Chat Pages: Latest  30  29  28  27  26  25  24  23  22  21  20  19  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |